| NSCLC | Non-small cell lung cancer |
| ER | Estrogen receptor |
| ERα | Estrogen receptor alpha |
| ERβ | Estrogen receptor beta |
| E2 | 17-Beta-estradiol |
| EVs | Extracellular vesicles |
| TME | Tumor microenvironment |
| TGF-β | Transforming growth factor beta |
| IL-6 | Interleukin 6 |
| IL-8 | Interleukin 8 |
| CCXL-16 | (C-X-C Motif) ligand 16 chemokine |
| PHTPP | 4-[2-Phenyl-5,7-bis(trifluoromethyl)pyrazolo [1,5-a]pyrimidin-3-yl]phenol |
| MPP | 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidin-1-ylethoxy)phenol]-1H-pyrazole |
| EMT | Epithelial–mesenchymal transition process |
| CDDP | Cisplatin |
| CAFs | Cancer-associated fibroblasts |
| FAP | Fibroblast-activated protein |
| PDGFR-β | Platelet-derived growth factor receptor-beta |
| PDPN | Podoplanin |
| α-SMA | Alpha smooth muscle actin |
| EGFR | Epidermal growth factor receptor |
| NFkB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| ERK | Extracellular signal-regulated kinase |